+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

Age: 18Years - 74YearsFEMALEPhase 2
47 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Indinol Forto 200 mg capsules compared to Visanne 2 mg tablets for treating endometriosis in females aged 18 to 45. This phase 3, open-label, randomized study is designed to test whether Indinol Forto is not less effective than Visanne. Participants have endometriosis confirmed by surgery within the past 60 months and experience moderate pelvic pain. Participants will be randomly assigned to one of two groups one group will take Indinol Forto capsules twice daily, and the other group will take Visanne tablets once daily, both for 24 weeks. Before treatment starts, there is a screening menstrual cycle to confirm eligibility. After completing the 24-week treatment period, participants will be observed for an additional month during a post-treatment follow-up. During the study, participants will daily record pelvic pain using a Visual Analog Scale, noting both cyclic and non-cyclic pain and vaginal bleeding intensity. Researchers will assess changes in average daily pelvic pain after 24 weeks of treatment compared to the screening period. Additional evaluations include quality of life, endometriosis symptoms, menstruation patterns, and lesion size. Safety and symptom changes will be monitored throughout the study and post-treatment period.

Age: 18Years - 45YearsFEMALEPhase 3
8 locations
S

Actively Recruiting

Researchers are conducting a multicenter, double-blind, placebo-controlled, randomized clinical trial to study children aged 3 to 12 years with acute respiratory viral infection ARVI. This trial aims to evaluate the safety and effectiveness of Raphamin in treating ARVI symptoms during the seasonal incidence of the illness. Enrollment starts with children aged 6 to 12 years and may expand to include those aged 3 to 12 years based on interim safety and efficacy results. Participants will be randomly assigned to receive either Raphamin or a placebo. Raphamin is given orally as tablets that dissolve in the mouth, with a specific dosing schedule over five days eight tablets on the first day taken at intervals, then one tablet three times daily on days two through five. The placebo group follows the same dosing regimen using placebo tablets. The treatment period lasts five days, followed by monitoring and follow-up visits. During the study, parents or caregivers will record their childs symptoms and body temperature twice daily in an electronic diary, including any use of fever-reducing medications and changes in health. Children will have several visits with healthcare providers on days 1, 5, and 7, plus a phone visit on day 14 for safety and symptom assessment. Laboratory tests and physical exams will be conducted to monitor progress and safety. The primary outcome is the time until ARVI symptoms resolve within 14 days.

Age: 3Years - 12YearsAll GendersPhase 3
35 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination drug containing clotrimazole and lactulose compared to clotrimazole alone in adult women diagnosed with candidal vulvovaginitis. The study aims to determine if the combination drug provides better clinical and microbiological recovery by Day 25 of treatment. This trial uses an adaptive design to assess how lactulose affects fungal infections in the vagina. Participants are randomly assigned to one of three groups one receiving vaginal suppositories with clotrimazole 100 mg and lactulose 300 mg, another receiving vaginal tablets with clotrimazole 100 mg alone, and a third group receiving vaginal suppositories with lactulose 300 mg alone. The study evaluates outcomes at several visits Day 8, Day 15, and Day 25, focusing on symptom improvement, microbiological response, and changes in vaginal bacteria. During the study, participants will undergo clinical assessments and laboratory tests to measure symptom severity and vaginal bacterial content, including molecular analysis of Lactobacillus levels. Patient satisfaction with the therapy will also be recorded. Safety and treatment responses will be monitored throughout the 25-day period, with the main result being the proportion of patients who achieve full clinical and microbiological recovery by Day 25.

Age: 18Years - 60YearsFEMALEPhase 2Phase 3
7 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of a liquid form of Rengalin for treating cough caused by acute viral upper respiratory tract infections in children aged 6 months to 3 years during the epidemic growth of influenza and ARVI. This randomized, double-blind, placebo-controlled trial compares Rengalin with a placebo to determine its effect on cough severity in young children. Participants will be randomly assigned to receive either 5 ml of Rengalin or a placebo orally three times a day for 7 days. The study includes initial screening and consent, followed by treatment and monitoring visits on days 1, 4, and 8, with a phone follow-up on day 14. On day 4, if needed, mucolytic ambroxol may be added while continuing the assigned study treatment. Parents will use an electronic diary to record cough severity twice daily throughout the study. During the study, researchers will assess symptoms, perform physical exams, and conduct laboratory tests including blood and urine analyses in at least half the participants. Safety and treatment adherence are closely monitored through visits and diaries. The main outcome is the percentage of patients responding to treatment by day 3, with secondary outcomes including changes in cough severity by day 7. The total study duration for participants is up to 14 days with ongoing observation.

Age: 6Months - 3YearsAll GendersPhase 3
30 locations
S

Actively Recruiting

Researchers are evaluating how Lipoproteina Lpa levels vary among patients with Atherosclerotic Cardiovascular Disease ASCVD in Russia and investigating the relationship between elevated Lpa levels and cardiovascular disease risk. The study aims to better understand the distribution of Lpa and its connection to cardiovascular events in this population. The study includes several phases Phase I is a cross-sectional study measuring Lpa levels in ASCVD patients aged 18 and older. Phase II involves a non-interventional, prospective cohort study with these patients and their first-degree relatives, including parents and children with elevated Lpa levels. The study observes patients and relatives over time without altering their treatments. Participants will undergo assessments to measure Lpa levels and cardiovascular events at baseline and during follow-up visits up to 24 months. Researchers will collect clinical data, including disability status, cardiovascular events, hospitalizations, and lipid-lowering therapy usage. The study monitors the percentage of patients with elevated Lpa, occurrence of cardiovascular complications, and treatment outcomes to understand the impact of Lpa levels on ASCVD progression and related health events.

Age: 18Years - 99YearsAll Genders
20 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects and mechanisms of Mexidol both injectable solution and oral tablets in patients experiencing the hyperacute and acute stages of ischemic stroke. This pilot, randomized, multicenter, open-label study aims to understand how Mexidol impacts clinical outcomes and brain imaging results compared to Glycine tablets, with 100 stroke patients and 20 healthy volunteers enrolled. The study focuses on safety and efficacy during early stroke treatment phases. The trial includes two patient groups one receives Mexidol solution intravenously twice daily for 10 days followed by Mexidol FORTE tablets three times daily for 60 days, alongside standard stroke care. The other group receives Glycine sublingual tablets once daily for 5 days with standard care. Healthy volunteers do not receive treatment but provide baseline biomarker data. Treatments are given according to current clinical guidelines. Participants undergo multiple evaluations including brain imaging MRI and CT, blood tests for biomarkers and coagulation, and clinical assessments like the National Institutes of Health Stroke Scale and modified Rankin Scale. Assessments occur at baseline, day 11, and follow-ups up to day 90. Safety and tolerability are monitored throughout the study, which spans from initial treatment to three months post-treatment.

Age: 18Years - 90YearsAll GendersPhase 4
9 locations
R

Actively Recruiting

This observational registry study focuses on patients aged 75 years and older who have a confirmed diagnosis of myocardial infarction. Started in 2020 and led by Ryazan State Medical University, the study collects clinical, demographic, instrumental, and prognostic data to better understand this population. The research uses statistical analysis software to evaluate significant differences in outcomes. The study tracks patients over a 10-year period, observing key health events such as all-cause death, recurrent myocardial infarction, stroke, and unplanned percutaneous coronary interventions. There are no experimental treatments or interventions involved since this is an observational study. Participants provide data through their medical records and routine clinical assessments during hospitalization. Researchers monitor important health outcomes over time to evaluate long-term risks and prognosis. The studys duration and follow-up allow for comprehensive outcome measurement and analysis of elderly patients with myocardial infarction.

Age: 75Years +All Genders
1 location
O

Actively Recruiting

Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.

Age: 18Years - 99YearsAll Genders
42 locations

1-10 of 13

1